Over the last decade, there have been substantial progress in the field of systemic therapy
for advanced renal cell carcinoma. Through the transition from treatment with cytokines to …

Management of metastatic renal cell carcinoma has been enriched by the advent of new
therapeutic compounds. The approval of new combination strategies between targeted …

Importance Novel immunotherapies, notably the immune checkpoint inhibitors, have been
shown to be efficacious in patients with advanced renal cell carcinoma, but innate or …

Immunotherapy (IO) with checkpoint inhibitors with or without anti-angiogenic tyrosine
kinase inhibitor (TKI)-based combinations have demonstrated superior efficacy over …

Purpose To evaluate the efficacy and safety of immune checkpoint inhibitor combination
therapy in advanced renal cell carcinoma (RCC). Methods We searched PubMed/Embase …

Background Clinical trials have demonstrated the superior efficacy of immune checkpoint
inhibitor (ICI)-based combination therapy over sunitinib, a multi-target tyrosine kinase …

Context There have been substantial changes in the management of patients with metastatic
renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based …

The treatment landscape of renal cell carcinoma is rapidly evolving, especially with the
introduction and approval of immune checkpoint inhibitor combination therapies. Clinical …

The treatment landscape of metastatic renal cell carcinoma (mRCC) is evolving very rapidly.
Until recently, targeted monotherapy with vascular endothelial growth factor (VEGF)-tyrosine …

Abstract Context Immune checkpoint inhibitors (ICIs) have reported unprecedented results in
the treatment of metastatic renal cell carcinoma (mRCC) patients, as monotherapy or in …